Pfizer
NEWS
Magnolia Neurosciences Corporation, co-founded by Accelerator Life Science Partners and The University of Texas MD Anderson Cancer Center, launched with a $31 million Series A financing.
Artios Pharma Limited, based in Cambridge, U.K., got a significant financial boost from Pfizer, AbbVie and Novartis through an $84 million (£65 million) Series B funding that will help advance its DNA Damage Response (DDR) programs for cancer treatments.
The pharma industry has developed ad campaigns to tout the efficacy of its branded products to consumers, often using celebrities to add his or her personal stamp onto a pharmaceutical product.
Here’s a roundup of biopharma companies that have announced hiring trends since the beginning of the year.
Yancopoulos, Regeneron’s founder and chief scientific officer, and Schleifer, chief executive officer, argue in the article that while drug affordability is important, the single-minded argument detracts from “the overwhelming health care crisis facing our society” and creates a negative image of an industry that provides substantial benefit to society.
The last two weeks have marked the second-quarterly financial report by numerous biopharma companies. Here’s a quick look at some of the major ones.
Cellectis announced it had appointed Stefan Scherer to the role of senior vice president Clinical Development and deputy chief medical officer.
Allergan is suing Pfizer over morphine-based opioid drugs, Kadian, that Allergan acquired in December 2008. Read more if you wish to know more about this matter.
Laekna, headquartered in Shanghai, China, signed a deal with Novartis Pharma AG for exclusive worldwide rights to two oral Novartis clinical-stage cancer drugs.
JOBS
IN THE PRESS